Dendreon CEO at WBBA Meeting: State Should Reject Income Tax, Inspire Young Scientists

Dendreon CEO Mitch Gold has said for years that he wants to make his company the anchor tenant for Seattle biotech. Now that his company has had a breakout success, he’s clearly got the full attention of 700 members of the biotech community who met this morning, wanting to know what can be done to create more companies like Dendreon.

For those just tuning in to this story, Dendreon made global news earlier this year when it won the first FDA approval for a therapy that actively stimulates the immune system to fight cancer. Seattle-based Dendreon (NASDAQ: [[ticker:DNDN]]) has been hiring hundreds of people to keep up with demand for this drug, and investors have given the company a market value of more than $5 billion. The company was worth about $38 million when Gold started as CEO on Jan. 1, 2003.

So Gold is no longer just another struggling biotech entrepreneur, but a guy hiring lots of smart people, and offering a therapy to men with prostate cancer that helps them live longer, with only mild side effects. Now that he has the floor, he took advantage of it at this morning’s event to make some unequivocal statements about what Washington can do to become a more vibrant biotech center.

First, Gold said the state shouldn’t pass a new state income tax that will make it harder to recruit talented executives. It could be a lot more aggressive about workforce training, like Georgia is. And the state could certainly do more to inspire and educate kids about careers in science.

I shared most of the pithy comments this morning in real-time while thumb-typing on my BlackBerry to my followers on Twitter. But I know most of the 700 people in this audience of biotech pros haven’t yet adopted the whole Twitter thing, so I thought I’d pass along the highlights here in these pages, which I know you’re reading (thanks for that, by the way!).

If you actually do want to start following me on Twitter, you can sign up for an account. You can click on my handle @ldtimmerman to start following the daily feed of stories that I write for Xconomy, some stories from others that I share, and the occasional musing about my love for running, mountaineering, and the Wisconsin Badgers. I’d also highly recommend you follow @adamfeuerstein, @matthewherper, @maverickny, @genomicslawyer, @fiercebiotech, @rleuty_biotech, @johncfierce, @michael_gilman, @popsalks to get started.

Dendreon CEO Mitch Gold
Dendreon CEO Mitch Gold

Anyway, to skeptical biotechies: I’ve learned that you can say a fair bit of stuff in 140 characters or less, and share interesting thoughts with people in real-time. Here’s a sampling of the material I knocked out on the BlackBerry this morning, in no particular order.

Mitch Gold: State of Georgia is really aggressive. Gave us $10m grant to train employees. Nothing like that in Wash St

Mitch Gold: Provenge took 15 years, $1.2B of capital. Not straightfwd path. Look to us as an example of perseverance in biotech.

Dendreon CEO Mitch Gold at WBBA mtg: Dendreon mkt cap was $38m when I started, $5B now. We are just getting started

Tom Clement: I raised $100m for a med device co, not possible today. Mirador raised $1m and got FDA approval, that’s the new way.

Jay Inslee: We are in a knife fight with other states to develop biotech industry. Need to set aside party differences to focus on this.

Mitch Gold: I hired COO Hans Bishop partly b/c Seattle has Gates Foundation, and his wife got a job there. Cluster effect very impt

Mitch Gold: Got to inspire youth. Every kid knows Bill Gates. Few know abt careers in science

Bob Nelsen: three of state’s top 4 life science investors will scale back if state income tax I-1098 passes

Mitch Gold: FDA lacks resources. Has rt intentions. We do ourselves a disservice if we lower the bar for approval.

Gov Gregoire: I have a $4.5b budget shortfall. Cuts are coming. Still need to invest in biotech, aerospace, greentech, IT

Gov Gregoire not mentioning the 40 percent budget cut to LS Discovery Fund. I’m skeptical of the job creation stats being tossed around

Gov Gregoire: many states mis-spent tobacco settlement $ on short term emergencies. WA st invested for future w/ life science discovery fund

Gov Gregoire: my 1st life science summit didn’t have nearly this many people. (About 700 people here today).

Mitch Gold: 1st met Jay Inslee in DC. He gets this industry. It’s not really abt creating jobs, but about changing lives of constituents

Mitch Gold: WA state shouldn’t pass income tax. Will make it tougher to recruit top East Coast talent

Mitch Gold: toughest challenge for us was getting top talent after Immunex got bought. That’s changing now that DNDN is a commercial org

Carl Feldbaum: FAA had to raise salaries to slow industry poaching of top employees. Not bad idea to help FDA staff

Carl Feldbaum: In 1906 at founding of FDA, food was more impt than drugs. Different story now.

Mitch Gold: FDA lacks resources. Has rt intentions. We do ourselves a disservice if we lower bar for approval.

Chris Rivera: WBBA bd unanimously opposed to WA st income tax I-1098.

Feldbaum: Chagas disease is little known killer in dev world. Genome of pathogen sequenced, still no good therapy. Needs industry champions

Carl Feldbaum: BIO was best job of my life, but I don’t miss working in DC. Political system too ‘bent out of shape, if not broken.’

WBBA’s Chris Rivera polling audience, on what group’s top priority should be. Attracting capital to WA is the winner. Recruit talent is No 2

Arch’s Bob Nelsen has a bumper sticker hanging on his name tag, against the proposed state income tax. Not afraid to stir the pot.

Heading to Gov Life Sciences conf/WBBA annl meeting in Bellevue. Fmr BIO pres Carl Feldbaum speaking, haven’t seen him in years. Will tweet

Author: Luke Timmerman

Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.